

Serial No. : 08/210,902
Filed : March 21, 1994

Q1
Q11
Q12
introducing a polynucleotide to said blood vessel after said mechanical treatment, said polynucleotide comprising a thymidine kinase gene;

expressing said thymidine kinase gene to produce thymidine kinase protein in cells of said blood vessel; and

then administering to said mammal an effective amount of a DNA replication-inhibiting nucleoside analog capable of being phosphorylated by said thymidine kinase protein [and], whereby said phosphorylated analog is preferentially [incorporating] incorporated [said phosphorylated analog] into the DNA of proliferating cells, and whereby said proliferating cells are killed.

Claim 4, line 2, following "vector is", please delete "in".

Q2
11.6 (Amended) The method of Claim ~~10~~ ^{11.6}, further comprising an adenoviral vector enhancer [elements] element, encapsidation [signals] signal and [origins] origin of replication [and other necessary adenoviral genes].

Q3
12.1 (Amended) The method of Claim 1, wherein said [suicide compound] nucleoside analog is ganciclovir or acyclovir.

Q4
13 (Amended) The method of Claim [13] 1, wherein said phosphorylated [compound] analog is further phosphorylated by intracellular enzymes.

REMARKS

Claims 13 and 16-20 have been canceled without prejudice.
Claims 1, 4, 7, 12 and 14 have been amended. Thus, Claims 1-12, 14